Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, IVF hartmann Holding AG's average EBITDA Per Share Growth Rate was -10.70% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 10.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 7.80% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 1.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of IVF hartmann Holding AG was 30.20% per year. The lowest was -32.10% per year. And the median was -0.70% per year.
IVF hartmann Holding AG (XSWX:VBSN) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
IVF hartmann Holding AG 3-Year EBITDA Growth Rate Related Terms
XSWX:VBSN vs ISRG, BDX, MDLN: 3-Year EBITDA Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, IVF hartmann Holding AG's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IVF hartmann Holding AG 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, IVF hartmann Holding AG's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where IVF hartmann Holding AG's 3-Year EBITDA Growth Rate falls into.
IVF hartmann Holding AG 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 10.00% mean?
IVF hartmann Holding AG (XSWX:VBSN) has a 3-Year EBITDA Growth Rate of 10.00% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for IVF hartmann Holding AG and its competitors. According to the industry distribution chart, IVF hartmann Holding AG ranks #332 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 48.1%.
Is IVF hartmann Holding AG's 3-Year EBITDA Growth Rate too high?
IVF hartmann Holding AG's current 3-Year EBITDA Growth Rate is 10.00%. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.20. IVF hartmann Holding AG's value of 10.00% is 22% above this industry median. Based on the distribution chart, IVF hartmann Holding AG ranks #332 out of 690 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, IVF hartmann Holding AG has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does IVF hartmann Holding AG's 3-Year EBITDA Growth Rate compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, IVF hartmann Holding AG ranks #332 out of 690 companies for 3-Year EBITDA Growth Rate. This puts IVF hartmann Holding AG in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.20. IVF hartmann Holding AG's value of 10.00% is 22% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IVF hartmann Holding AG's current 3-Year EBITDA Growth Rate of 10.00% is 22% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for IVF hartmann Holding AG and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IVF hartmann Holding AG's current 3-Year EBITDA Growth Rate is 10.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IVF hartmann Holding AG stock overvalued right now?
Based on GuruFocus' analysis, IVF hartmann Holding AG (XSWX:VBSN) is currently considered Fairly Valued. The stock's GF Value™ is CHF143.59, compared to a current price of CHF133.50 — trading 7% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 10.00% and 22% above the Medical Devices & Instruments industry median of 8.20. IVF hartmann Holding AG's overall GF Score™ is 76/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For IVF hartmann Holding AG (XSWX:VBSN), the current 3-Year EBITDA Growth Rate is 10.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IVF hartmann Holding AG (XSWX:VBSN) Overvalued in 2026?
Based on GuruFocus' analysis, IVF hartmann Holding AG stock appears to be undervalued.
The current stock price of CHF133.50 is trading 7% below its estimated GF Value™ of CHF143.59.
GuruFocus considers IVF hartmann Holding AG to be Fairly Valued.
Key valuation signals for XSWX:VBSN:
3-Year EBITDA Growth Rate: 10.00%
GF Value™: CHF143.59 vs. price of CHF133.50 (7% below fair value)
Industry Position: 22% above the Medical Devices & Instruments median (#332 of 690)
No single metric tells the full story. See the XSWX:VBSN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IVF hartmann Holding AG engages in production and supply of medical, pharmaceutical and hygiene products in Switzerland, it offers products such as surgical disposable, disposable dental, first aid, therapeutic plaster, cotton wool, wound care among others. The company operates in four segment wound care, incontinence management, infection management and Other group activities.
76GF Score
Get the complete analysis for XSWX:VBSN
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:VBSN has been successfully added to your 
